T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 4.32 USD 6.14% Market Closed
Market Cap: 126.6m USD
Have any thoughts about
TriSalus Life Sciences Inc?
Write Note

TriSalus Life Sciences Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

TriSalus Life Sciences Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
T
TriSalus Life Sciences Inc
NASDAQ:TLSI
Total Current Assets
$20.9m
CAGR 3-Years
118%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nextdoor Holdings Inc
NYSE:KIND
Total Current Assets
$566.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Flame Acquisition Corp
NYSE:SOC
Total Current Assets
$364.4k
CAGR 3-Years
243%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Core Scientific Inc
NASDAQ:CORZ
Total Current Assets
$97m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Symbotic Inc
NASDAQ:SYM
Total Current Assets
$1.4B
CAGR 3-Years
75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rumble Inc
NASDAQ:RUM
Total Current Assets
$238m
CAGR 3-Years
357%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
131.6m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
4.92 USD
Undervaluation 12%
Intrinsic Value
Price
T

See Also

What is TriSalus Life Sciences Inc's Total Current Assets?
Total Current Assets
20.9m USD

Based on the financial report for Dec 31, 2023, TriSalus Life Sciences Inc's Total Current Assets amounts to 20.9m USD.

What is TriSalus Life Sciences Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
118%

Over the last year, the Total Current Assets growth was 5 116%. The average annual Total Current Assets growth rates for TriSalus Life Sciences Inc have been 118% over the past three years .

Back to Top